Welcome to our dedicated page for Sage Therapeutic news (Ticker: SAGE), a resource for investors and traders seeking the latest updates and insights on Sage Therapeutic stock.
Sage Therapeutics (SAGE) is a clinical-stage biopharmaceutical leader pioneering treatments for central nervous system disorders, including depression and rare neurological conditions. This page provides investors and researchers with a comprehensive repository of official company updates and third-party analysis.
Access timely announcements on clinical trial milestones, regulatory developments, and strategic collaborations shaping the future of neuroscience therapeutics. Our curated feed includes earnings reports, research publications, and partnership disclosures critical for evaluating SAGE’s progress in addressing unmet medical needs.
Key content focuses on GABA/NMDA receptor-targeted therapies, pipeline advancements for postpartum depression treatments, and epilepsy-related innovations. Bookmark this page to monitor how Sage Therapeutics’ scientific expertise translates into potential market opportunities within the competitive CNS pharmaceutical landscape.
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company focused on brain health, has announced it will host a live webcast on Wednesday, July 31, 2024, at 4:30 p.m. ET. The webcast will cover the company's second quarter 2024 financial results and provide updates on recent business activities. Investors and interested parties can access the webcast through the Investor page on Sage's website at investor.sagerx.com. A replay of the webcast will be available after the event and archived for up to 30 days.
Sage Therapeutics announced topline results from its Phase 2 SURVEYOR Study for Huntington's Disease (HD). The study met its primary endpoint, highlighting a significant cognitive difference between healthy participants and those with HD, as measured by the HD-Cognitive Assessment Battery (HD-CAB).
Dalzanemdor (SAGE-718) was generally well-tolerated, with no new safety signals observed. The study involved 40 participants with HD and 29 healthy controls. While the study wasn't designed to show a significant difference between dalzanemdor and placebo, a small numerical improvement was noted in cognition for those on dalzanemdor.
Sage plans to apply these findings to future research and expects to report further data from the dalzanemdor program in late 2024, including studies on Alzheimer's Disease and additional HD cognitive impairment.
Sage Therapeutics (NASDAQ: SAGE), a biopharmaceutical company focused on brain health, announced its participation in the Goldman Sachs 45th Annual Global Healthcare Conference. The event will include a fireside chat scheduled for June 12, 2024, at 2:00 p.m. ET in Miami, FL. Interested parties can view a live webcast of the presentation on Sage's Investor page. A replay will be available for 30 days post-event.
Sage Therapeutics, a biopharmaceutical company, will participate in investor conferences in May, including the 2024 RBCCM Global Healthcare Conference and BofA Securities 2024 Health Care Conference. The Company aims to create a world with better brain health. Live webcasts and replays of the presentations will be available on Sage's Investor page.
FAQ
What is the current stock price of Sage Therapeutic (SAGE)?
What is the market cap of Sage Therapeutic (SAGE)?
